Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech's Ion AmpliSeq Exome CSP Program Adds 12 Members

NEW YORK (GenomeWeb News) – Twelve organizations in the US, Europe, and Asia Pacific have joined Life Technologies' Ion AmpliSeq Exome Certified Service Provider program, bringing total membership to more than 30, Life Tech said today.

The new members are US-based Kashi Clinical Laboratories, RUCDR Infinite Biologics, WuXi AppTec, Molecular Resource Center, and Research and Testing Laboratory; Europe's Fasteris, Eurofins MWG Operon, NIMGenetics, Genomax, and Cellcall; Australia's Lotterywest State Biomedical Facility; and South Korea's DNA Link.

In addition, molecular testing company Cynvenio Biosystems has joined the Ion Certified Service Provider program, of which the Ion AmpliSeq Exome CSP is a part.

In order to be a CSP for AmpliSeq exome sequencing, service providers must demonstrate that they can generate at least 30 million reads per exome using 50 nanograms of starting DNA, cover 88 percent to 90 percent of the exome at 20x, and do the sequencing for an all-in reagents cost of $400. Additionally, providers must be able to sequence two exomes in one two-hour run with a total turnaround time of two days.

"The popularity of the Ion AmpliSeq Exome Certified Service Provider program has grown rapidly, reflecting significant underlying demand for fast, easy-to-use Ion AmpliSeq Exome sequencing," Maneesh Jain, vice president of marketing and business development at Ion Torrent, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.